Evaluation of the effect celecoxib against radiotherapy induced acute toxicities in the patients with prostate cancer compared with placebo group.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016020626401N1

Enrollment

Registered

2016-03-17

Start date

2015-02-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer. Malignant neoplasm of prostate

Interventions

Intervention 1: Intervention group: celecoxib

200 mg

twice daily

in course of radiotherapy

2 month. Intervention 2: Control group: placebo

2 month.

Treatment - Drugs

Intervention group: celecoxib

Control group: placebo

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Inclusion criteria: Histologically confirmed prostate cancer; normal levels of hemoglobin; leukocytes; platelets; creatinine; urea; bilirubine in the patients. Exclusion criteria: clinical and radioghraphic evidence of distant metastasis before or during the trial; inability to receive celecoxib; simultaneous participation in another clinical trial; receive any other NSAIDs; patients with severe and uncontrolled cardiovascular; kidney; liver; inflammatory intestinal disease; coagulation disorders.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Urinary and bowel toxicities. Timepoint: weekly. Method of measurement: questionnaire.	—

Secondary

Measure	Time frame
Blood factors. Timepoint: Start and ending in radiotherapy. Method of measurement: sampling.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaeede Mirmohammadirad

Shahid Beheshti University of Medical Sciences

saeede.rad1392@gmail.com+98 22718531

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026